High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome

Blood Advances
Peter HollanderIngrid Glimelius

Abstract

Immune checkpoint inhibition targeting the programmed death receptor (PD)-1 pathway is a novel treatment approach in relapsed and refractory classical Hodgkin lymphoma (cHL). Identifying patients with a high risk of treatment failure could support the use of PD-1 inhibitors as front-line treatment. Our aim was to investigate the prognostic impact of PD-1, programmed death-ligand 1 (PD-L1), and PD-L2 in the tumor microenvironment in diagnostic biopsies of patients with cHL. Patients from Denmark and Sweden, diagnosed between 1990 and 2007 and ages 15 to 86 years, were included. Tissue microarray samples were available from 387 patients. Immunohistochemistry was used to detect PD-1, PD-L1, and PD-L2, and the proportions of positive cells were calculated. Event-free survival (EFS; time to treatment failure) and overall survival (OS) were analyzed using Cox proportional hazards regression. High proportions of both PD-1+ (hazard ratio [HR], 1.77; 95% confidence interval [CI], 1.10-2.86) and PD-L1+ (HR = 1.89; 95% CI, 1.08-3.30) leukocytes in the microenvironment were associated with inferior EFS in a multivariate analysis (adjusted for white blood cell count >15 × 109/L, hemoglobin <105 g/L, albumin <40 g/L, B symptoms, extranodal i...Continue Reading

References

Feb 1, 1993·Annals of Internal Medicine·J ConcatoT R Holford
Feb 3, 2005·Journal of the National Cancer Institute·Karin Ekström SmedbyHans-Olov Adami
Mar 10, 2010·Biomarker Insights·Leandro Luongo de MatosMaria Aparecida da Silva Pinhal
Mar 12, 2010·The New England Journal of Medicine·Christian SteidlRandy D Gascoyne
Feb 15, 2011·Annual Review of Immunology·Shane Crotty
May 24, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D AzambujaN Spector
Aug 21, 2012·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·L V RiellaA Chandraker
Jan 10, 2013·Current Opinion in Immunology·Joel CrespoWeiping Zou
May 2, 2014·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Ariel PedoeemAdam Mor
Aug 8, 2014·The Cancer Journal·Sheng Yao, Lieping Chen
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Jun 13, 2015·Applied Immunohistochemistry & Molecular Morphology : AIMM·TuDung T NguyenFriederike H Kreisel
Jul 25, 2015·Nature Reviews. Immunology·E John Wherry, Makoto Kurachi
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Dec 19, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Young Wha KohJooryung Huh
Apr 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaretha G M RoemerMargaret A Shipp
Apr 29, 2016·Clinical and Experimental Immunology·A L Rodríguez-PereaP A Velilla
Dec 20, 2016·Journal of Internal Medicine·I Glimelius, A Diepstra
Dec 27, 2016·Frontiers in Immunology·Kankana BardhanVassiliki A Boussiotis
Mar 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D AzambujaN Spector

❮ Previous
Next ❯

Citations

Aug 28, 2018·Hematological Oncology·Priscilla Brito da SilvaOtavio C G Baiocchi
Jul 11, 2020·The American Journal of Surgical Pathology·Ashley VolaricAlejandro A Gru
Feb 16, 2018·HemaSphere·Ryan H Moy, Anas Younes
May 7, 2020·Journal of the Egyptian National Cancer Institute·Mona Y Y Abd AllahShaimaa El-Ashwah
Dec 8, 2020·Leukemia & Lymphoma·Jorge Vela-OjedaLaura Arcelia Montiel-Cervantes
Mar 16, 2021·Blood Advances·Alex Reza GholihaGunilla Enblad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.